1
High dosages of naproxen exert a near complete COX-1 inhibition, which suggests a possible protective effect for MI compared with rofecoxib
However, COX-1 enzymes also play a protective role in maintaining the stomach
A very large randomized trial among moderate risk cardiovascular patients is comparing the cardiovascular safety of celecoxib, naproxen, and ibuprofen
June 4, 2009 (Nashville, Tennessee) — One of the first large studies to look at the safety of different nonsteroidal anti-inflammatory drugs safety profile of naproxen in the context of the NSAID class
9,10 This retrospective cohort study examined 5 individual NSAIDs (naproxen, ibuprofen
7 It included 31 RCTs (N = 120,000 patients) that had more than 100 patient-years of follow-up Naproxen is Long Acting and Ibuprofen is Short Acting
Inhibitors of cyclo-oxogenase (COX) are widely used anti-inflammatory drugs
17 In this study, patients taking rofecoxib 50 mg had a five-fold increased risk of MI compared with naproxen 1 At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to cardiovascular safety
In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 ± 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100–200 mg bid), ibuprofen (600–800 mg
Immediate Release (naproxen sodium): 550 mg orally once, followed by 275 mg orally every 6 to 8 hours or 550 mg orally every 12 hours as needed
Proceed down the algorithm on the basis of pain control and risk factors